Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Quality of Life | 42 | 2025 | 1108 | 5.720 |
Why?
|
| Psychometrics | 22 | 2025 | 355 | 2.880 |
Why?
|
| Sickness Impact Profile | 16 | 2013 | 46 | 2.690 |
Why?
|
| Surveys and Questionnaires | 27 | 2025 | 2584 | 2.440 |
Why?
|
| Health Surveys | 11 | 2023 | 306 | 2.180 |
Why?
|
| Self Report | 10 | 2020 | 366 | 1.910 |
Why?
|
| Disability Evaluation | 6 | 2017 | 214 | 1.340 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2023 | 112 | 1.250 |
Why?
|
| Factor Analysis, Statistical | 8 | 2020 | 104 | 1.250 |
Why?
|
| Health Status | 10 | 2025 | 449 | 1.140 |
Why?
|
| Reproducibility of Results | 16 | 2025 | 1546 | 1.140 |
Why?
|
| Health Status Indicators | 3 | 2015 | 98 | 1.120 |
Why?
|
| Models, Statistical | 4 | 2020 | 306 | 1.070 |
Why?
|
| Data Collection | 4 | 2014 | 384 | 1.030 |
Why?
|
| Adult | 35 | 2025 | 15729 | 0.880 |
Why?
|
| Middle Aged | 37 | 2025 | 16232 | 0.880 |
Why?
|
| Cost of Illness | 5 | 2016 | 154 | 0.870 |
Why?
|
| Pharyngitis | 1 | 2023 | 12 | 0.860 |
Why?
|
| Aged | 34 | 2025 | 13285 | 0.850 |
Why?
|
| Severity of Illness Index | 5 | 2024 | 1447 | 0.820 |
Why?
|
| Smoking | 3 | 2020 | 830 | 0.820 |
Why?
|
| Chronic Disease | 7 | 2023 | 731 | 0.820 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 80 | 0.810 |
Why?
|
| Multiple Chronic Conditions | 1 | 2022 | 33 | 0.780 |
Why?
|
| Male | 42 | 2025 | 27480 | 0.750 |
Why?
|
| Activities of Daily Living | 9 | 2012 | 298 | 0.750 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2019 | 117 | 0.730 |
Why?
|
| Mindfulness | 1 | 2021 | 64 | 0.720 |
Why?
|
| Prostatic Neoplasms | 3 | 2020 | 326 | 0.720 |
Why?
|
| Software | 3 | 2012 | 366 | 0.680 |
Why?
|
| Cause of Death | 1 | 2020 | 200 | 0.680 |
Why?
|
| Humans | 57 | 2025 | 59284 | 0.680 |
Why?
|
| Headache | 3 | 2003 | 63 | 0.660 |
Why?
|
| Aged, 80 and over | 15 | 2025 | 5063 | 0.650 |
Why?
|
| Female | 37 | 2025 | 30798 | 0.650 |
Why?
|
| Autism Spectrum Disorder | 1 | 2021 | 178 | 0.600 |
Why?
|
| Young Adult | 11 | 2025 | 4318 | 0.570 |
Why?
|
| Adolescent | 17 | 2024 | 5914 | 0.550 |
Why?
|
| Knee Injuries | 1 | 2017 | 47 | 0.550 |
Why?
|
| Fatigue | 2 | 2014 | 104 | 0.550 |
Why?
|
| Heart Failure | 3 | 2023 | 861 | 0.520 |
Why?
|
| Osteoarthritis | 3 | 2020 | 129 | 0.510 |
Why?
|
| Translating | 1 | 2015 | 17 | 0.490 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2017 | 124 | 0.490 |
Why?
|
| Arthritis, Rheumatoid | 5 | 2013 | 324 | 0.480 |
Why?
|
| Comorbidity | 7 | 2020 | 1084 | 0.460 |
Why?
|
| Drug Therapy | 1 | 2014 | 61 | 0.450 |
Why?
|
| Cross-Sectional Studies | 9 | 2024 | 2461 | 0.440 |
Why?
|
| Information Systems | 1 | 2013 | 30 | 0.430 |
Why?
|
| Musculoskeletal Diseases | 2 | 2020 | 101 | 0.420 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2014 | 666 | 0.410 |
Why?
|
| User-Computer Interface | 2 | 2012 | 129 | 0.390 |
Why?
|
| Monitoring, Ambulatory | 1 | 2012 | 56 | 0.390 |
Why?
|
| Osteoarthritis, Knee | 1 | 2017 | 383 | 0.380 |
Why?
|
| Research Design | 2 | 2014 | 565 | 0.380 |
Why?
|
| Acute Coronary Syndrome | 1 | 2015 | 256 | 0.380 |
Why?
|
| Models, Theoretical | 4 | 2015 | 257 | 0.380 |
Why?
|
| Outpatients | 1 | 2012 | 131 | 0.370 |
Why?
|
| Treatment Outcome | 8 | 2017 | 5141 | 0.360 |
Why?
|
| Calibration | 4 | 2015 | 65 | 0.350 |
Why?
|
| Mental Health | 5 | 2020 | 348 | 0.340 |
Why?
|
| United States | 14 | 2024 | 7492 | 0.330 |
Why?
|
| Anemia | 1 | 2010 | 117 | 0.330 |
Why?
|
| Stress, Psychological | 2 | 2021 | 443 | 0.290 |
Why?
|
| Restless Legs Syndrome | 1 | 2007 | 6 | 0.280 |
Why?
|
| Subacute Care | 1 | 2007 | 9 | 0.280 |
Why?
|
| Migraine Disorders | 2 | 2003 | 45 | 0.270 |
Why?
|
| Managed Care Programs | 2 | 2004 | 93 | 0.260 |
Why?
|
| Nervous System Diseases | 1 | 2007 | 95 | 0.250 |
Why?
|
| Longitudinal Studies | 5 | 2017 | 1224 | 0.250 |
Why?
|
| Disease Management | 1 | 2007 | 220 | 0.250 |
Why?
|
| Program Evaluation | 1 | 2007 | 483 | 0.240 |
Why?
|
| Affective Symptoms | 1 | 2004 | 16 | 0.230 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 266 | 0.230 |
Why?
|
| Cough | 2 | 2024 | 182 | 0.230 |
Why?
|
| Computer Systems | 1 | 2003 | 15 | 0.230 |
Why?
|
| Hyperkalemia | 1 | 2023 | 23 | 0.220 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2010 | 675 | 0.220 |
Why?
|
| Immunocompromised Host | 1 | 2024 | 94 | 0.220 |
Why?
|
| Double-Blind Method | 6 | 2014 | 684 | 0.220 |
Why?
|
| Analysis of Variance | 2 | 2016 | 576 | 0.220 |
Why?
|
| Psoriasis | 1 | 2004 | 51 | 0.220 |
Why?
|
| Physical and Rehabilitation Medicine | 1 | 2003 | 2 | 0.220 |
Why?
|
| Rehabilitation | 1 | 2003 | 6 | 0.220 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 148 | 0.210 |
Why?
|
| Interpersonal Relations | 2 | 2019 | 150 | 0.210 |
Why?
|
| Multimorbidity | 1 | 2022 | 38 | 0.200 |
Why?
|
| Life Tables | 1 | 2020 | 24 | 0.180 |
Why?
|
| Marital Status | 1 | 2020 | 43 | 0.180 |
Why?
|
| SEER Program | 1 | 2020 | 63 | 0.180 |
Why?
|
| Confidence Intervals | 3 | 2013 | 256 | 0.180 |
Why?
|
| Finasteride | 2 | 2012 | 5 | 0.180 |
Why?
|
| Depression | 1 | 2007 | 857 | 0.170 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 450 | 0.160 |
Why?
|
| Medicare | 1 | 2004 | 601 | 0.160 |
Why?
|
| Japan | 3 | 2023 | 60 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 869 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 287 | 0.160 |
Why?
|
| Social Support | 1 | 2021 | 357 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2021 | 917 | 0.150 |
Why?
|
| Renal Dialysis | 1 | 2019 | 184 | 0.140 |
Why?
|
| Rheumatic Diseases | 1 | 2017 | 41 | 0.140 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 258 | 0.140 |
Why?
|
| Age Factors | 1 | 2020 | 1518 | 0.130 |
Why?
|
| Personal Satisfaction | 2 | 2014 | 78 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2012 | 522 | 0.130 |
Why?
|
| Germany | 1 | 2015 | 51 | 0.130 |
Why?
|
| Thyroid Diseases | 1 | 2015 | 26 | 0.130 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 2323 | 0.120 |
Why?
|
| Self-Assessment | 2 | 2007 | 54 | 0.120 |
Why?
|
| Single-Blind Method | 1 | 2015 | 134 | 0.120 |
Why?
|
| Concept Formation | 1 | 2014 | 16 | 0.120 |
Why?
|
| Adaptation, Psychological | 2 | 2007 | 263 | 0.120 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2014 | 1 | 0.120 |
Why?
|
| Somatostatin | 1 | 2014 | 21 | 0.120 |
Why?
|
| Anticarcinogenic Agents | 2 | 2012 | 76 | 0.120 |
Why?
|
| Tobacco Products | 1 | 2015 | 75 | 0.120 |
Why?
|
| Goiter | 1 | 2014 | 9 | 0.110 |
Why?
|
| Smoking Prevention | 1 | 2015 | 162 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2020 | 1907 | 0.110 |
Why?
|
| Methotrexate | 2 | 2006 | 76 | 0.110 |
Why?
|
| Antirheumatic Agents | 3 | 2007 | 213 | 0.110 |
Why?
|
| Patient Preference | 1 | 2014 | 74 | 0.110 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2012 | 7 | 0.100 |
Why?
|
| Emotions | 1 | 2014 | 217 | 0.100 |
Why?
|
| Computers, Handheld | 1 | 2012 | 31 | 0.100 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 795 | 0.100 |
Why?
|
| Dyspnea | 1 | 2012 | 108 | 0.090 |
Why?
|
| Stroke | 1 | 2020 | 1135 | 0.090 |
Why?
|
| Role Playing | 1 | 2010 | 7 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2017 | 2435 | 0.090 |
Why?
|
| Risk Factors | 1 | 2020 | 4997 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2023 | 3095 | 0.090 |
Why?
|
| Depressive Disorder | 1 | 2013 | 291 | 0.090 |
Why?
|
| Prevalence | 2 | 2012 | 1279 | 0.090 |
Why?
|
| Qualitative Research | 1 | 2014 | 605 | 0.090 |
Why?
|
| Immunoconjugates | 2 | 2007 | 84 | 0.080 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 413 | 0.080 |
Why?
|
| Models, Psychological | 2 | 2010 | 92 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 439 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 563 | 0.070 |
Why?
|
| Erectile Dysfunction | 1 | 2007 | 32 | 0.070 |
Why?
|
| International Cooperation | 2 | 2006 | 84 | 0.070 |
Why?
|
| Program Development | 1 | 2007 | 210 | 0.070 |
Why?
|
| Interviews as Topic | 1 | 2007 | 483 | 0.060 |
Why?
|
| United Kingdom | 1 | 2024 | 69 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2004 | 34 | 0.060 |
Why?
|
| Potassium | 1 | 2023 | 109 | 0.050 |
Why?
|
| Intellectual Property | 1 | 2003 | 6 | 0.050 |
Why?
|
| Telephone | 1 | 2003 | 121 | 0.050 |
Why?
|
| Polyhydroxyethyl Methacrylate | 1 | 2002 | 6 | 0.050 |
Why?
|
| Tetrazoles | 1 | 2002 | 20 | 0.050 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2002 | 30 | 0.050 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2003 | 43 | 0.050 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2002 | 45 | 0.050 |
Why?
|
| Time Factors | 2 | 2007 | 3567 | 0.050 |
Why?
|
| Acute Disease | 1 | 2024 | 658 | 0.050 |
Why?
|
| Intermittent Claudication | 1 | 2002 | 48 | 0.050 |
Why?
|
| Risk Adjustment | 1 | 2002 | 91 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2003 | 158 | 0.050 |
Why?
|
| Communication | 1 | 2007 | 552 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 61 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2004 | 219 | 0.050 |
Why?
|
| Needs Assessment | 1 | 2002 | 188 | 0.050 |
Why?
|
| Attitude to Health | 1 | 2003 | 275 | 0.050 |
Why?
|
| Disabled Persons | 1 | 2003 | 205 | 0.050 |
Why?
|
| Walking | 1 | 2002 | 229 | 0.040 |
Why?
|
| Social Participation | 1 | 2020 | 14 | 0.040 |
Why?
|
| Cultural Competency | 1 | 2020 | 50 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 57 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 1093 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 451 | 0.040 |
Why?
|
| Cognition | 1 | 2003 | 459 | 0.040 |
Why?
|
| Hypertension | 1 | 2004 | 600 | 0.040 |
Why?
|
| Child | 2 | 2024 | 4298 | 0.040 |
Why?
|
| Algorithms | 1 | 2003 | 986 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 781 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 248 | 0.040 |
Why?
|
| Pain | 1 | 2020 | 406 | 0.030 |
Why?
|
| Abatacept | 2 | 2007 | 63 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 55 | 0.030 |
Why?
|
| Psychological Theory | 1 | 2011 | 26 | 0.020 |
Why?
|
| Educational Status | 1 | 2011 | 271 | 0.020 |
Why?
|
| Self Concept | 1 | 2010 | 104 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2010 | 147 | 0.020 |
Why?
|
| Computer-Assisted Instruction | 1 | 2010 | 80 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2011 | 207 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 403 | 0.020 |
Why?
|
| Cholestenone 5 alpha-Reductase | 1 | 2007 | 1 | 0.020 |
Why?
|
| Placebos | 1 | 2007 | 72 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 338 | 0.020 |
Why?
|
| Los Angeles | 1 | 2004 | 11 | 0.010 |
Why?
|
| Chicago | 1 | 2004 | 24 | 0.010 |
Why?
|
| Health Maintenance Organizations | 1 | 2004 | 87 | 0.010 |
Why?
|
| Specialization | 1 | 2004 | 73 | 0.010 |
Why?
|
| Fee-for-Service Plans | 1 | 2004 | 67 | 0.010 |
Why?
|
| Cross-Cultural Comparison | 1 | 2004 | 45 | 0.010 |
Why?
|
| Medicine | 1 | 2004 | 56 | 0.010 |
Why?
|
| Europe | 1 | 2004 | 182 | 0.010 |
Why?
|
| Boston | 1 | 2004 | 329 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 485 | 0.010 |
Why?
|
| Intracranial Arterial Diseases | 1 | 2002 | 5 | 0.010 |
Why?
|
| Linear Models | 1 | 2004 | 419 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2002 | 115 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 196 | 0.010 |
Why?
|
| Etanercept | 1 | 2002 | 31 | 0.010 |
Why?
|
| Exercise Test | 1 | 2002 | 233 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2002 | 327 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2004 | 645 | 0.010 |
Why?
|